Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | TK1 | P04183 | 5/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALB | P02768 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | DHFR | P00374 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL339966 | 0.83 | ALDH1A1 (0.41) | ALDH1A1NPSR1TK1LMNAALB | |
| SCHEMBL30841853 | 0.83 | ALDH1A1 (0.41) | ALDH1A1NPSR1TK1LMNAALB | |
| SCHEMBL31307084 | 0.76 | ALDH1A1 (0.41) | ALDH1A1NPSR1TK1LMNAALB | |
| SCHEMBL8897185 | 0.76 | ALDH1A1 (0.36) | ALDH1A1NPSR1TK1 | |
| SCHEMBL8895915 | 0.72 | TYMP (0.44) | ALDH1A1NPSR1TK1 | |
| SCHEMBL4748323 | 0.71 | TK1 (0.35) | ALDH1A1NPSR1TK1LMNAALB | |
| SCHEMBL29943756 | 0.71 | TK1 (0.43) | ALDH1A1TK1LMNAALBPOLB | |
| SCHEMBL2294 | 0.71 | TK1 (0.43) | ALDH1A1TK1LMNAALBPOLB | |
| SCHEMBL4749295 | 0.69 | PYGM (0.39) | ALDH1A1NPSR1TK1LMNAALB | |
| SCHEMBL7543828 | 0.68 | LMNA (0.42) | ALDH1A1NPSR1TK1LMNAALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6001828-A | Use of tumor factor inhibitors together with antiviral agents and therapeutic compositions thereof against HIV infection | ANDRULIS JR PETER (US) | 1999-12-14 | — | — | US | disclosed |
| EP-0712310-A1 | USE OF TUMOR NECROSIS FACTOR INHIBITORS TOGETHER WITH ANTIVIRAL AGENTS AND THERAPEUTIC COMPOSITIONS THEREOF AGAINST HIV INFECTION | Andrulis Pharmaceuticals Corporation (US) | 1996-05-22 | — | — | EP | disclosed |
| WO-1995004525-A2 | USE OF TUMOR NECROSIS FACTOR INHIBITORS TOGETHER WITH ANTIVIRAL AGENTS AND THERAPEUTIC COMPOSITIONS THEREOF AGAINST HIV INFECTION | ANDRULIS PHARMACEUTICALS CORPORATION (US) | 1995-02-16 | — | — | WO | disclosed |